e-learning
resources
Munich 2014
Monday, 08.09.2014
Animal models in respiratory drug development
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A molecule derived from mycobacterium tuberculosis
Cpn60.1 (compound Y) inhibits lung inflammation induced by LPS in mice
Y. Vasquez, A. Lightfoot, C. Page (London, United Kingdom)
Source:
International Congress 2014 – Animal models in respiratory drug development
Session:
Animal models in respiratory drug development
Session type:
Poster Discussion
Number:
1795
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Vasquez, A. Lightfoot, C. Page (London, United Kingdom).
A molecule derived from mycobacterium tuberculosis
Cpn60.1 (compound Y) inhibits lung inflammation induced by LPS in mice. Eur Respir J 2014; 44: Suppl. 58, 1795
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Rapamycin protects OVA induced asthma in mice through regulating autophagy
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015
Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Anti-inflammatory action of Gibberellin in lung epithelial cells is mediated by modification of NF-κB related kinase expression
Source: International Congress 2014 – Mechanistic studies of the airway epithelium
Year: 2014
Role of peroxiredoxin 6 in lipopolysaccharide-induced mucin production in mice
Source: Annual Congress 2013 –Molecular biology: state-of-the-art 2013
Year: 2013
Recombinant human pulmonary surfactant protein-D (rhSP-D) modulates Th2 responses and suppresses IgE-facilitated allergen binding to B cells
Source: Annual Congress 2013 –Genetics and mechanisms of, and tests for, allergy
Year: 2013
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Enhanced inflammatory gene expression in bronchial epithelial cells from asthmatic patients: Attenuation by a Brd4 mimic
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
The human cathelicidin LL37 and mitochondrial DAMPs induce airway inflammation in epithelial cells and mice
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
Glucocorticoid-induced transcriptional regulators in human airway cells and airways
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Plant proteinase inhibitor from
crataeva tapia (CrataBl)
attenuates inflammation and remodelling induced by elastase in mice
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Cryptotanshinone attenuates airway Inflammation induced by cigarette smoke in mice
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Inhibitors of apoptosis proteins in asthmatic airway inflammation
Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Year: 2013
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept